Ixekizumab
Treatment for Psoriasis
Typical Dosage: 160mg SC at week 0, then 80mg SC every 2 weeks for 12 weeks, then every 4 weeks
Effectiveness
90%
Safety Score
58%
Clinical Trials
48
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
58
DangerousModerateSafe
Treatment Details
Dosage Range
160mg SC at week 0, then 80mg SC every 2 weeks for 12 weeks, then every 4 weeks
Time to Effect
2-4 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
2(Treat 2 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$98,000
Monitoring:$600
Side Effect Mgmt:$500
Total Annual:$99,100
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$160,000/QALY
QALYs Gained
1.4
Outcome-Based Costs
Cost per Responder
$120,854
Cost per Remission
$283,143
Active Clinical Trials
4 active trials recruiting for Ixekizumab in Psoriasis
Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis
NCT06374979NOT YET RECRUITINGPHASE2, PHASE3
50 participants
INTERVENTIONAL
Started: May 1, 2025
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
NCT06588283ACTIVE NOT RECRUITINGPHASE3
250 participants
INTERVENTIONAL
Birmingham, United States +71 more
Started: Sep 30, 2024
Ixekizumab Versus Secukizumab in Over 70-year-old Patients with Psoriasis
NCT06811558NOT YET RECRUITINGNA
100 participants
INTERVENTIONAL
Started: Feb 1, 2025
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
NCT04537689RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Outram Park, Singapore
Started: Dec 10, 2020
Completed Clinical Trials
15 completed trials for Ixekizumab in Psoriasis
A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
NCT03073213COMPLETEDPHASE1
32 participants
INTERVENTIONAL
Changsha, China +2 more
Started: Apr 13, 2017
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis
NCT02387801COMPLETEDPHASE3
12 participants
INTERVENTIONAL
New York, United States
Started: Apr 1, 2015
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
NCT03942042COMPLETEDPHASE4
12 participants
INTERVENTIONAL
Nagoya, Japan +6 more
Started: Jul 5, 2019
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis
NCT02718898COMPLETEDPHASE3
149 participants
INTERVENTIONAL
Santa Ana, United States +33 more
Started: Apr 1, 2016
A Study in Participants With Moderate to Severe Psoriasis
NCT01107457COMPLETEDPHASE2
142 participants
INTERVENTIONAL
Bakersfield, United States +33 more
Started: Apr 1, 2010
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
NCT05855967COMPLETEDPHASE4
250 participants
INTERVENTIONAL
Vizag, India +13 more
Started: Jun 27, 2023
A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
NCT03364309COMPLETEDPHASE3
438 participants
INTERVENTIONAL
Beijing, China +16 more
Started: Apr 26, 2018
A Study of Ixekizumab in Participants With Plaque Psoriasis
NCT02993471COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Anaheim, United States +2 more
Started: Dec 22, 2016
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
NCT02513550COMPLETEDPHASE3
1.26K participants
INTERVENTIONAL
Birmingham, United States +124 more
Started: Aug 1, 2015
Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis
NCT01777191COMPLETEDPHASE3
204 participants
INTERVENTIONAL
Anaheim, United States +24 more
Started: Mar 1, 2013
A Study in Japanese Participants With Moderate-to-Severe Psoriasis
NCT01624233COMPLETEDPHASE3
91 participants
INTERVENTIONAL
Ehime, Japan +16 more
Started: Jun 1, 2012
A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
NCT03573323COMPLETEDPHASE4
1.03K participants
INTERVENTIONAL
Birmingham, United States +123 more
Started: Nov 9, 2018
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
NCT03073200COMPLETEDPHASE3
201 participants
INTERVENTIONAL
Birmingham, United States +68 more
Started: Mar 28, 2017
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
NCT02561806COMPLETEDPHASE3
302 participants
INTERVENTIONAL
Wein, Austria +47 more
Started: Oct 1, 2015
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
NCT01695239COMPLETEDPHASE3
417 participants
INTERVENTIONAL
Birmingham, United States +115 more
Started: Dec 1, 2012
Showing 20 of 48 total trials